Assessment of DNA Integrity, Applications for Cancer Research

Advances in Clinical Chemistry

Volumn 70, Issue , 2015, Pages 197-246

  Zonta, Eleonora ^a   Nizard, Philippe ^a   Taly, Valérie ^a  

^a Therapeutic Implications Laboratoire d'Excellence GR Ex   (France)

Author keywords

ALU elements; Cancer biomarker; Cell free circulating DNA; Circulating tumor DNA; DNA integrity index; DNA quality; DNA size profiling; DPCR; QPCR

Indexed keywords

DNA; TUMOR MARKER;

ANIMAL; BLOOD; DEVICES; ELECTROPHORESIS; EQUIPMENT DESIGN; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN; MICROFLUIDIC ANALYSIS; NEOPLASMS; PROCEDURES; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; SPECTROPHOTOMETRY;

ANIMALS; BIOMARKERS, TUMOR; DNA, NEOPLASM; ELECTROPHORESIS; EQUIPMENT DESIGN; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MICROFLUIDIC ANALYTICAL TECHNIQUES; NEOPLASMS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; SPECTROPHOTOMETRY;

EID: 84952719744     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/bs.acc.2015.03.002     Document Type: Chapter

References (192)

1. Heydt C., Fassunke J., Kunstlinger H., Ihle M.A., Konig K., Heukamp L.C., et al. Comparison of pre-analytical FFPE sample preparation methods and their impact on massively parallel sequencing in routine diagnostics. PLoS One 2014, 9(8):e104566.
2. Simbolo M., Gottardi M., Corbo V., Fassan M., Mafficini A., Malpeli G., et al. DNA qualification workflow for next generation sequencing of histopathological samples. PLoS One 2013, 8(6):e62692.
3. Wang B.G., Huang H.Y., Chen Y.C., Bristow R.E., Kassauei K., Cheng C.C., et al. Increased plasma DNA integrity in cancer patients. Cancer Res. 2003, 63:3966-3968.
4. Sunami E., Vu A.T., Nguyen S.L., Hoon D.S. Analysis of methylated circulating DNA in cancer patients' blood. Methods Mol. Biol. 2009, 507:349-356.
5. McDermott G.P., Do D., Litterst C.M., Maar D., Hindson C.M., Steenblock E.R., et al. Multiplexed target detection using DNA-binding dye chemistry in droplet digital PCR. Anal. Chem. 2013, 85:11619-11627.
6. Didelot A., Kotsopoulos S.K., Lupo A., Pekin D., Li X., Atochin I., et al. Multiplex picoliter-droplet digital PCR for quantitative assessment of DNA integrity in clinical samples. Clin. Chem. 2013, 59:815-823.
7. Glasel J.A. Validity of nucleic acid purities monitored by 260nm/280nm absorbance ratios. Biotechniques 1995, 18:62-63.
8. Barbas C.F., Burton D.R., Scott J.K., Silverman G.J. Quantitation of DNA and RNA. Cold Spring Harb. Protoc. 2007, 2007:pdb.ip47.
9. Robertson C. Spectrophotometry's Next-Generation Technology 2003, American Biotechnology Laboratory, NanoDrop Technologies, Inc, Rockland, DE 19732, U.S.A.
10. Rengarajan K., Cristol S.M., Mehta M., Nickerson J.M. Quantifying DNA concentrations using fluorometry: a comparison of fluorophores. Mol. Vis. 2002, 8:416-421.
11. Deo S. Essentials of nucleic acid analysis: a robust approach. Anal. Bioanal. Chem. 2008, 392:321-322.
12. Johnson I., Spence M.T.Z. The Molecular Probes® Handbook-A Guide to Fluorescent Probes and Labeling Technologies 2010, Life Technologies, Inc., Eugene, OR. 11th ed.
13. Batel R., Jaksic Z., Bihari N., Hamer B., Fafandel M., Chauvin C., et al. A microplate assay for DNA damage determination (fast micromethod). Anal. Biochem. 1999, 270:195-200.
14. Swerdlow H., Gesteland R. Capillary gel electrophoresis for rapid, high resolution DNA sequencing. Nucleic Acids Res. 1990, 18:1415-1419.
15. Barry A., Cohen S. Quality assessment of genomic DNA degradation: alternative to gel electrophoresis overcomes limitations of traditional methods. Genet. Eng. Biotechnol. News 2013, 33(16).
16. Sun M., Lin J.S., Barron A.E. Ultrafast, efficient separations of large-sized dsDNA in a blended polymer matrix by microfluidic chip electrophoresis: a design of experiments approach. Electrophoresis 2011, 32:3233-3240.
17. Wu D., Qin J., Lin B. Electrophoretic separations on microfluidic chips. J. Chromatogr. A 2008, 1184:542-559.
18. White R.A., Blainey P.C., Fan H.C., Quake S.R. Digital PCR provides sensitive and absolute calibration for high throughput sequencing. BMC Genomics 2009, 10:116.
19. Fang Z.L., Fang Q. Development of a low-cost microfluidic capillary-electrophoresis system coupled with flow-injection and sequential-injection sample introduction (review). Fresenius J. Anal. Chem. 2001, 370:978-983.
20. Bustin S.A., Benes V., Garson J.A., Hellemans J., Huggett J., Kubista M., et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin. Chem. 2009, 55:611-622.
21. Brisco M.J., Latham S., Bartley P.A., Morley A.A. Incorporation of measurement of DNA integrity into qPCR assays. Biotechniques 2010, 49:893-897.
22. van Beers E.H., Joosse S.A., Ligtenberg M.J., Fles R., Hogervorst F.B., Verhoef S., et al. A multiplex PCR predictor for aCGH success of FFPE samples. Br. J. Cancer 2006, 94:333-337.
23. Wang F., Wang L., Briggs C., Sicinska E., Gaston S.M., Mamon H., et al. DNA degradation test predicts success in whole-genome amplification from diverse clinical samples. J. Mol. Diagn. 2007, 9:441-451.
24. Walker J.A., Kilroy G.E., Xing J., Shewale J., Sinha S.K., Batzer M.A. Human DNA quantitation using Alu element-based polymerase chain reaction. Anal. Biochem. 2003, 315:122-128.
25. Swango K.L., Timken M.D., Chong M.D., Buoncristiani M.R. A quantitative PCR assay for the assessment of DNA degradation in forensic samples. Forensic Sci. Int. 2006, 158:14-26.
26. Siwoski A., Ishkanian A., Garnis C., Zhang L., Rosin M., Lam W.L. An efficient method for the assessment of DNA quality of archival microdissected specimens. Mod. Pathol. 2002, 15:889-892.
27. Sah S., Chen L., Houghton J., Kemppainen J., Marko A.C., Zeigler R., et al. Functional DNA quantification guides accurate next-generation sequencing mutation detection in formalin-fixed, paraffin-embedded tumor biopsies. Genome Med. 2013, 5:77.
28. Didelot A., Le Corre D., Luscan A., Cazes A., Pallier K., Emile J.F., et al. Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples. Exp. Mol. Pathol. 2012, 92:275-280.
29. Schander C., Kenneth H.M. DNA, PCR and formalinized animal tissue-a short review and protocols. Org. Divers. Evol. 2003, 3:195-205.
30. Srinivasan M., Sedmak D., Jewell S. Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am. J. Pathol. 2002, 161:1961-1971.
31. Salvianti F., Pinzani P., Verderio P., Ciniselli C.M., Massi D., De Giorgi V., et al. Multiparametric analysis of cell-free DNA in melanoma patients. PLoS One 2012, 7(11):e49843.
32. Pinzani P., Salvianti F., Zaccara S., Massi D., De Giorgi V., Pazzagli M., et al. Circulating cell-free DNA in plasma of melanoma patients: qualitative and quantitative considerations. Clin. Chim. Acta 2011, 412:2141-2145.
33. Umetani N., Giuliano A.E., Hiramatsu S.H., Amersi F., Nakagawa T., Martino S., et al. Prediction of breast tumor progression by integrity of free circulating DNA in serum. J. Clin. Oncol. 2006, 24:4270-4276.
34. Tangkijvanich P., Hourpai N., Rattanatanyong P., Wisedopas N., Mahachai V., Mutirangura A. Serum LINE-1 hypomethylation as a potential prognostic marker for hepatocellular carcinoma. Clin. Chim. Acta 2007, 379:127-133.
35. Umetani N., Kim J., Hiramatsu S., Reber H.A., Hines O.J., Bilchik A.J., et al. Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin. Chem. 2006, 52:1062-1069.
36. Sunami E., Vu A.T., Nguyen S.L., Giuliano A.E., Hoon D.S. Quantification of LINE1 in circulating DNA as a molecular biomarker of breast cancer. Ann. N. Y. Acad. Sci. 2008, 1137:171-174.
37. Batzer M.A., Deininger P.L. Alu repeats and human genomic diversity. Nat. Rev. Genet. 2002, 3:370-379.
38. Hasler J., Samuelsson T., Strub K. Useful 'junk': alu RNAs in the human transcriptome. Cell. Mol. Life Sci. 2007, 64:1793-1800.
39. Bodega B., Orlando V. Repetitive elements dynamics in cell identity programming, maintenance and disease. Curr. Opin. Cell Biol. 2014, 31:67-73.
40. Bennett E.A., Keller H., Mills R.E., Schmidt S., Moran J.V., Weichenrieder O., Devine S.E. Active Alu retrotransposons in the human genome. Genome Res. 2008, 18:1875-1883.
41. Wolff E.M., Byun H.M., Han H.F., Sharma S., Nichols P.W., Siegmund K.D., et al. Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer. PLoS Genet. 2010, 6(4):e1000917.
42. Laurent-Puig P., Pekin D., Normand C., Kotsopoulos S.K., Nizard P., Perez Toralla K., et al. Clinical relevance of KRAS-mutated sub-clones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy. Clin. Cancer Res. 2015, 21(5):1087-1097.
43. Lehner J., Stotzer O.J., Fersching D.M., Nagel D., Holdenrieder S. Plasma DNA integrity indicates response to neoadjuvant chemotherapy in patients with locally confined breast cancer. Int. J. Clin. Pharmacol. Ther. 2013, 51:59-62.
44. Hao T.B., Shi W., Shen X.J., Qi J., Wu X.H., Wu Y., et al. Circulating cell-free DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer. Br. J. Cancer 2014, 111:1482-1489.
45. Mead R., Duku M., Bhandari P., Cree I.A. Circulating tumour markers can define patients with normal colons, benign polyps, and cancers. Br. J. Cancer 2011, 105:239-245.
46. Mouliere F., Robert B., Arnau Peyrotte E., Del Rio M., Ychou M., Molina F., et al. High fragmentation characterizes tumour-derived circulating DNA. PLoS One 2011, 6(9):e23418.
47. Mouliere F., El Messaoudi S., Pang D., Dritschilo A., Thierry A.R. Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer. Mol. Oncol. 2014, 8:927-941.
48. Lehner J., Stotzer O.J., Fersching D., Nagel D., Holdenrieder S. Circulating plasma DNA and DNA integrity in breast cancer patients undergoing neoadjuvant chemotherapy. Clin. Chim. Acta 2013, 425:206-211.
49. Madhavan D., Wallwiener M., Bents K., Zucknick M., Nees J., Schott S., et al. Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis. Breast Cancer Res. Treat. 2014, 146:163-174.
50. Deligezer U., Eralp Y., Akisik E.Z., Akisik E.E., Saip P., Topuz E., et al. Effect of adjuvant chemotherapy on integrity of free serum DNA in patients with breast cancer. Ann. N. Y. Acad. Sci. 2008, 1137:175-179.
51. Deligezer U., Eralp Y., Akisik Ebru E., Akisik Elif Z., Saip P., Topuz E., et al. Size distribution of circulating cell-free DNA in sera of breast cancer patients in the course of adjuvant chemotherapy. Clin. Chem. Lab. Med. 2008, 46(3):311-317.
52. Stötzer O., Lehner J., Fersching-Gierlich D., Nagel D., Holdenrieder S. Diagnostic relevance of plasma DNA and DNA integrity for breast cancer. Tumour Biol. 2014, 35:1183-1191.
53. Schmidt B., Weickmann S., Witt C., Fleischhacker M. Integrity of cell-free plasma DNA in patients with lung cancer and nonmalignant lung disease. Ann. N. Y. Acad. Sci. 2008, 1137:207-213.
54. Sriram K.B., Relan V., Clarke B.E., Duhig E.E., Windsor M.N., Matar K.S., et al. Pleural fluid cell-free DNA integrity index to identify cytologically negative malignant pleural effusions including mesotheliomas. BMC Cancer 2012, 12:428-439.
55. Ellinger J., Bastian P.J., Haan K.I., Heukamp L.C., Buettner R., Fimmers R., et al. Noncancerous PTGS2 DNA fragments of apoptotic origin in sera of prostate cancer patients qualify as diagnostic and prognostic indicators. Int. J. Cancer 2008, 122:138-143.
56. Hanley R., Rieger-Christ K.M., Canes D., Emara N.R., Shuber A.P., Boynton K.A., et al. DNA integrity assay: a plasma-based screening tool for the detection of prostate cancer. Clin. Cancer Res. 2006, 12:4569-4574.
57. Ellinger J., Wittkamp V., Albers P., Perabo F.G., Mueller S.C., von Ruecker A., et al. Cell-free circulating DNA: diagnostic value in patients with testicular germ cell cancer. J. Urol. 2009, 181:363-371.
58. Ellinger J., Albers P., Müller S.C., Von Ruecker A., Bastian P.J. Circulating mitochondrial DNA in the serum of patients with testicular germ cell cancer as a novel noninvasive diagnostic biomarker. BJU Int. 2009, 104:48-52.
59. Ellinger J., Müller D.C., Müller S.C., Hauser S., Heukamp L.C., von Ruecker A., et al. Circulating mitochondrial DNA in serum: a universal diagnostic biomarker for patients with urological malignancies. Urol. Oncol. 2012, 30:509-515.
60. Jiang W.W., Zahurak M., Goldenberg D., Milman Y., Park H.L., Westra W.H., et al. Increased plasma DNA integrity index in head and neck cancer patients. Int. J. Cancer 2006, 119:2673-2676.
61. Holdenrieder S., Burges A., Reich O., Spelsberg F.W., Stieber P. DNA integrity in plasma and serum of patients with malignant and benign diseases. Ann. N. Y. Acad. Sci. 2008, 1137:162-170.
62. Gang F., Guorong L., An Z., Anne G.-P., Christian G., Jacques T. Prediction of clear cell renal cell carcinoma by integrity of cell-free DNA in serum. Urology 2010, 75:262-265.
63. Gao Y.J., He Y.J., Yang Z.L., Shao H.Y., Zuo Y., Bai Y., et al. Increased integrity of circulating cell-free DNA in plasma of patients with acute leukemia. Clin. Chem. Lab. Med. 2010, 48:1651-1656.
64. Shi W., Lv C., Qi J., Zhao W., Wu X., Jing R., et al. Prognostic value of free DNA quantification in serum and cerebrospinal fluid in glioma patients. J. Mol. Neurosci. 2012, 46:470-475.
65. Sykes P.J., Neoh S.H., Brisco M.J., Hughes E., Condon J., Morley A.A. Quantitation of targets for PCR by use of limiting dilution. Biotechniques 1992, 13:444-449.
66. Vogelstein B., Kinzler K.W. Digital PCR. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:9236-9241.
67. Taly V., Pekin D., El Abed A., Laurent-Puig P. Detecting biomarkers with microdroplet technology. Trends Mol. Med. 2012, 18:405-416.
68. Taly V., Pekin D., Benhaim L., Kotsopoulos S.K., Le Corre D., Li X., et al. Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. Clin. Chem. 2013, 59(12):1722-1731.
69. Dressman D., Yan H., Traverso G., Kinzler K.W., Vogelstein B. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:8817-8822.
70. Nakano M., Komatsu J., Matsuura S., Takashima K., Katsura S., Mizuno A. Single-molecule PCR using water-in-oil emulsion. J. Biotechnol. 2003, 102:117-124.
71. Theberge A.B., Courtois F., Schaerli Y., Fischlechner M., Abell C., Hollfelder F., et al. Microdroplets in microfluidics: an evolving platform for discoveries in chemistry and biology. Angew. Chem. Int. Ed. Engl. 2010, 49:5846-5868.
72. Pekin D., Skhiri Y., Baret J.C., Le Corre D., Mazutis L., Ben Salem C., et al. Quantitative and sensitive detection of rare mutations using droplet-based microfluidics. Lab Chip 2011, 11(13):2156-2166.
73. Hindson B.J., Ness K.D., Masquelier D.A., Belgrader P., Heredia N.J., Makarewicz A.J., et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal. Chem. 2011, 83:8604-8610.
74. Hatch A.C., Fisher J.S., Tovar A.R., Hsieh A.T., Lin R., Pentoney S.L., et al. 1-Million droplet array with wide-field fluorescence imaging for digital PCR. Lab Chip 2011, 11:3838-3845.
75. Zhong Q., Bhattacharya S., Kotsopoulos S., Olson J., Taly V., Griffiths A.D., et al. Multiplex digital PCR: breaking the one target per color barrier of quantitative PCR. Lab Chip 2011, 11:2167-2174.
76. Sedlak R.H., Kuypers J., Jerome K.R. A multiplexed droplet digital PCR assay performs better than qPCR on inhibition prone samples. Diagn. Microbiol. Infect. Dis. 2014, 80(4):285-286.
77. Tsui N.B., Jiang P., Chow K.C., Su X., Leung T.Y., Sun H., et al. High resolution size analysis of fetal DNA in the urine of pregnant women by paired-end massively parallel sequencing. PLoS One 2012, 7:e48319.
78. Fan H.C., Blumenfeld Y.J., Chitkara U., Hudgins L., Quake S.R. Analysis of the size distributions of fetal and maternal cell-free DNA by paired-end sequencing. Clin. Chem. 2010, 56:1279-1286.
79. Jiang P., Chan C.W., Chan K.C., Cheng S.H., Wong J., Wong V.W., et al. Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc. Natl. Acad. Sci. U. S. A. 2015, 112(11):E1317-1325.
80. Fan H.C., Blumenfeld Y.J., Chitkara U., Hudgins L., Quake S.R. Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:16266-16271.
81. Liu K.J., Brock M.V., Shih I.-M., Wang T.-H. Decoding circulating nucleic acids in human serum using microfluidic single molecule spectroscopy. J. Am. Chem. Soc. 2010, 132:5793-5798.
82. Liu K.J., Wang T.-H. Cylindrical illumination confocal spectroscopy: rectifying the limitations of confocal single molecule spectroscopy through one-dimensional beam shaping. Biophys. J. 2008, 95:2964-2975.
83. Blum F. Der formaldehyde als hartungsmittel. Z. Wiss. Mikr. 1893, 10:314-315.
84. Michalik S. Overcoming poor quality DNA. Drug Discov. Devel. 2008, 11:24-30.
85. Lewis F., Maughan N.J., Smith V., Hillan K., Quirke P. Unlocking the archive-gene expression in paraffin-embedded tissue. J. Pathol. 2001, 195:66-71.
86. Yost S.E., Smith E.N., Schwab R.B., Bao L., Jung H., Wang X., et al. Identification of high-confidence somatic mutations in whole genome sequence of formalin-fixed breast cancer specimens. Nucleic Acids Res. 2012, 40(14):e107.
87. Wessels L.F., van Welsem T., Hart A.A., van't Veer L.J., Reinders M.J., Nederlof P.M. Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors. Cancer Res. 2002, 62:7110-7117.
88. van Beers E.H., van Welsem T., Wessels L.F., Li Y., Oldenburg R.A., Devilee P., et al. Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations. Cancer Res. 2005, 65:822-827.
89. Cannon-Albright L.A., Cooper K.G., Georgelas A., Bernard P.S. High quality and quantity genome-wide germline genotypes from FFPE normal tissue. BMC Res. Notes 2011, 4:159.
90. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 2012, 366:883-892.
91. El Messaoudi S., Rolet F., Mouliere F., Thierry A.R. Circulating cell free DNA: preanalytical considerations. Clin. Chim. Acta 2013, 424:222-230.
92. Polo S.E. Reshaping chromatin after DNA Damage: the choreography of histone proteins. J. Mol. Biol. 2015, 427(3):626-636.
93. Butt A.N., Swaminathan R. Overview of circulating nucleic acids in plasma/serum. Ann. N. Y. Acad. Sci. 2008, 1137:236-242.
94. Mandel P., Metais P. Les acides nucleiques du plasma sanguin chez lhomme. C. R. Seances Soc. Biol. Fil. 1948, 142:241-243.
95. Pinzani P., Salvianti F., Orlando C., Pazzagli M. Circulating cell-free DNA in cancer. Methods Mol. Biol. 2014, 1160:133-145.
96. Jiang W.W., Masayesva B., Zahurak M., Carvalho A.L., Rosenbaum E., Mambo E., et al. Increased mitochondrial DNA content in saliva associated with head and neck cancer. Clin. Cancer Res. 2005, 11:2486-2491.
97. Jahr S., Hentze H., Englisch S., Hardt D., Fackelmayer F.O., Hesch R.D., et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001, 61:1659-1665.
98. Diehl F., Li M., Dressman D., He Y., Shen D., Szabo S., et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:16368-16373.
99. Ralla B., Stephan C., Meller S., Dietrich D., Kristiansen G., Jung K. Nucleic acid-based biomarkers in body fluids of patients with urologic malignancies. Crit. Rev. Clin. Lab. Sci. 2014, 51:200-231.
100. Diehl F., Schmidt K., Durkee K.H., Moore K.J., Goodman S.N., Shuber A.P., et al. Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. Gastroenterology 2008, 135:489-498.
101. De Maio G., Rengucci C., Zoli W., Calistri D. Circulating and stool nucleic acid analysis for colorectal cancer diagnosis. World J. Gastroenterol. 2014, 20:957-967.
102. Rengucci C., Maio G.D., Menghi M., Scarpi E., Guglielmo S., Fusaroli P., et al. Improved stool DNA integrity method for early colorectal cancer diagnosis. Cancer Epidemiol. Biomarkers Prev. 2014, 23:2553-2560.
103. Beck J., Urnovitz H.B., Riggert J., Clerici M., Schutz E. Profile of the circulating DNA in apparently healthy individuals. Clin. Chem. 2009, 55:730-738.
104. Tan E.M., Schur P.H., Carr R.I., Kunkel H.G. Deoxybonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus. J. Clin. Invest. 1966, 45:1732-1740.
105. Ayala W., Moore L.V., Hess E.L. The purple color reaction given by diphenylamine reagent I with normal and rheumatic fever sera 1. J. Clin. Invest. 1951, 30:781-785.
106. Leon S.A., Ehrlich G.E., Shapiro B., Labbate V.A. Free DNA in the serum of rheumatoid arthritis patients. J. Rheumatol. 1977, 4:139-143.
107. Leon S.A., Shapiro B., Sklaroff D.M., Yaros M.J. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977, 37:646-650.
108. Bartoloni E., Ludovini V., Alunno A., Pistola L., Bistoni O., Crino L., et al. Increased levels of circulating DNA in patients with systemic autoimmune diseases: a possible marker of disease activity in Sjogren's syndrome. Lupus 2011, 20:928-935.
109. Jylhava J., Lehtimaki T., Jula A., Moilanen L., Kesaniemi Y.A., Nieminen M.S., et al. Circulating cell-free DNA is associated with cardiometabolic risk factors: the Health 2000 Survey. Atherosclerosis 2014, 233:268-271.
110. Coimbra S., Catarino C., Costa E., Oliveira H., Figueiredo A., Rocha-Pereira P., et al. Circulating cell-free DNA levels in Portuguese patients with psoriasis vulgaris according to severity and therapy. Br. J. Dermatol. 2014, 170:939-942.
111. Atamaniuk J., Vidotto C., Tschan H., Bachl N., Stuhlmeier K.M., Müller M.M. Increased concentrations of cell-free plasma DNA after exhaustive exercise. Clin. Chem. 2004, 50:1668-1670.
112. Dwivedi D.J., Toltl L.J., Swystun L.L., Pogue J., Liaw K.L., Weitz J.I., et al. Prognostic utility and characterization of cell-free DNA in patients with severe sepsis. Crit. Care 2012, 16(4):R151.
113. Lo Y.M.D., Rainer T.H., Chan L.Y.S., Hjelm N.M., Cocks R.A. Plasma DNA as a prognostic marker in trauma patients. Clin. Chem. 2000, 46:319-323.
114. Lam N.Y.L., Rainer T.H., Chiu R.W.K., Joynt G.M., Lo Y.M.D. Plasma mitochondrial DNA concentrations after trauma. Clin. Chem. 2004, 50:213-216.
115. Shoham Y., Krieger Y., Perry Z.H., Shaked G., Bogdanov-Berezovsky A., Silberstein E., et al. Admission cell free DNA as a prognostic factor in burns: quantification by use of a direct rapid fluorometric technique. BioMed Res. Int. 2014, 2014(306580):5.
116. Shimony A., Zahger D., Gilutz H., Goldstein H., Orlov G., Merkin M., et al. Cell free DNA detected by a novel method in acute ST-elevation myocardial infarction patients. Acute Card. Care 2010, 12:109-111.
117. Sriram K.B., Relan V., Clarke B.E., Duhig E.E., Yang I.A., Bowman R.V., et al. Diagnostic molecular biomarkers for malignant pleural effusions. Future Oncol. 2011, 7:737-752.
118. Perkins G., Yap T.A., Pope L., Cassidy A.M., Dukes J.P., Riisnaes R., et al. Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers. PLoS One 2012, 7(11):e47020.
119. Lee C.C., Fecher L.A., Gallia G.L., Gibbs P., Le D., Giuntoli R.L., et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 2014, 6(224):224ra24.
120. Diaz L.A., Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J. Clin. Oncol. 2014, 32:579-586.
121. Gown A.M. Current issues in ER and HER2 testing by IHC in breast cancer. Mod. Pathol. 2008, 21:S8-S15.
122. Lumachi F., Basso S.M.M., Bonamini M., Marzano B., Milan E., Waclaw B.U., et al. Relationship between preoperative serum markers CA 15-3 and CEA and relapse of the disease in elderly (>65 years) women with breast cancer. Anticancer Res. 2010, 30:2331-2334.
123. Carter H.B., Albertsen P.C., Barry M.J., Etzioni R., Freedland S.J., Greene K.L., et al. Early detection of prostate cancer: AUA guideline. J. Urol. 2013, 190:419-426.
124. Dawson S.-J., Tsui D.W.Y., Murtaza M., Biggs H., Rueda O.M., Chin S.-F., et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 2013, 368:1199-1209.
125. Henry N.L., Hayes D.F. Cancer biomarkers. Mol. Oncol. 2012, 6:140-146.
126. Locker G.Y., Hamilton S., Harris J., Jessup J.M., Kemeny N., Macdonald J.S., et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J. Clin. Oncol. 2006, 24:5313-5327.
127. Heidenreich A., Abrahamsson P.-A., Artibani W., Catto J., Montorsi F., Van Poppel H., et al. Early detection of prostate cancer: European Association of Urology recommendation. Eur. Urol. 2013, 64:347-354.
128. Diehl F., Schmidt K., Choti M.A., Romans K., Goodman S., Li M., et al. Circulating mutant DNA to assess tumor dynamics. Nat. Med. 2008, 14:985-990.
129. Fleischhacker M., Schmidt B. Circulating nucleic acids (CNAs) and cancer-a survey. Biochim. Biophys. Acta 2007, 1775:181-232.
130. Shapiro B., Chakrabarty M., Cohn E.M., Leon S.A. Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer 1983, 51:2116-2120.
131. Flamini E., Mercatali L., Nanni O., Calistri D., Nunziatini R., Zoli W., et al. Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer. Clin. Cancer Res. 2006, 12:6985-6988.
132. Frattini M., Gallino G., Signoroni S., Balestra D., Lusa L., Battaglia L., et al. Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer. Cancer Lett. 2008, 263:170-181.
133. Lecomte T., Ceze N., Dorval E., Laurent-Puig P. Circulating free tumor DNA and colorectal cancer. Gastroenterol. Clin. Biol. 2010, 34:662-681.
134. Heitzer E., Ulz P., Geigl J.B. Circulating tumor DNA as a liquid biopsy for cancer. Clin. Chem. 2015, 61:112-123.
135. van der Vaart M., Pretorius P.J. Is the role of circulating DNA as a biomarker of cancer being prematurely overrated?. Clin. Biochem. 2010, 43:26-36.
136. Devonshire A.S., Whale A.S., Gutteridge A., Jones G., Cowen S., Foy C.A., et al. Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification. Anal. Bioanal. Chem. 2014, 406:6499-6512.
137. N.A.o.C. Biochemistry.
138. Lecomte T., Berger A., Zinzindohoue F., Micard S., Landi B., Blons H., et al. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int. J. Cancer 2002, 100:542-548.
139. Sorenson G.D., Pribish D.M., Valone F.H., Memoli V.A., Bzik D.J., Yao S.L. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol. Biomarkers Prev. 1994, 3:67-71.
140. Sorenson G.D. Detection of mutated KRAS2 sequences as tumor markers in plasma/serum of patients with gastrointestinal cancer. Clin. Cancer Res. 2000, 6:2129-2137.
141. Mulcahy H.E., Lyautey J., Lederrey C., qi Chen X., Anker P., Alstead E.M., et al. A prospective study of K-ras mutations in the plasma of pancreatic cancer patients. Clin. Cancer Res. 1998, 4:271-275.
142. Jung K., Fleischhacker M., Rabien A. Cell-free DNA in the blood as a solid tumor biomarker-a critical appraisal of the literature. Clin. Chim. Acta 2010, 411:1611-1624.
143. Elshimali Y.I., Khaddour H., Sarkissyan M., Wu Y., Vadgama J.V. The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients. Int. J. Mol. Sci. 2013, 14:18925-18958.
144. Wagner J. Free DNA-new potential analyte in clinical laboratory diagnostics?. Biochem. Med. (Zagreb) 2012, 22:24-38.
145. Yu J., Gu G., Ju S. Recent advances in clinical applications of circulating cell-free DNA integrity. Lab. Med. 2014, 45:6-11.
146. Sita-Lumsden A., Fletcher C.E., Dart D.A., Brooke G.N., Waxman J., Bevan C.L. Circulating nucleic acids as biomarkers of prostate cancer. Biomark. Med. 2013, 7:867-877.
147. Lim S.H., Becker T.M., Chua W., Caixeiro N.J., Ng W.L., Kienzle N., et al. Circulating tumour cells and circulating free nucleic acid as prognostic and predictive biomarkers in colorectal cancer. Cancer Lett. 2014, 346:24-33.
148. Marzese D.M., Hirose H., Hoon D.S. Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients. Expert Rev. Mol. Diagn. 2013, 13:827-844.
149. Crowley E., Di Nicolantonio F., Loupakis F., Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat. Rev. Clin. Oncol. 2013, 10:472-484.
150. Wiksell H., Schassburger K.U., Janicijevic M., Leifland K., Lofgren L., Rotstein S., et al. Prevention of tumour cell dissemination in diagnostic needle procedures. Br. J. Cancer 2010, 103(11):1706-1709.
151. Loughran C.F., Keeling C.R. Seeding of tumour cells following breast biopsy: a literature review. Br. J. Radiol. 2011, 84:869-874.
152. Bedard P.L., Hansen A.R., Ratain M.J., Siu L.L. Tumour heterogeneity in the clinic. Nature 2013, 501:355-364.
153. Esposito A., Bardelli A., Criscitiello C., Colombo N., Gelao L., Fumagalli L., et al. Monitoring tumor-derived cell-free DNA in patients with solid tumors: clinical perspectives and research opportunities. Cancer Treat. Rev. 2014, 40:648-655.
154. Diaz L.A., Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J. Clin. Oncol. 2014, 32:579-586.
155. Misale S., Yaeger R., Hobor S., Scala E., Janakiraman M., Liska D., et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012, 486:532-536.
156. Li M., Chen W.D., Papadopoulos N., Goodman S.N., Bjerregaard N.C., Laurberg S., et al. Sensitive digital quantification of DNA methylation in clinical samples. Nat. Biotechnol. 2009, 27:858-863.
157. Richardson A.L., Iglehart J.D. BEAMing up personalized medicine: mutation detection in blood. Clin. Cancer Res. 2012, 18:3209-3211.
158. Del Vescovo V., Grasso M., Barbareschi M., Denti M. MicroRNAs as lung cancer biomarkers. World J. Clin. Oncol. 2014, 5:604-620.
159. Yong E. Cancer biomarkers: written in blood. Nature 2014, 511:524.
160. van der Vaart M., Pretorius P.J. Circulating DNA. Its origin and fluctuation. Ann. N. Y. Acad. Sci. 2008, 1137:18-26.
161. Stroun M., Lyautey J., Lederrey C., Olson-Sand A., Anker P. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin. Chim. Acta 2001, 313:139-142.
162. Lo Y.M., Zhang J., Leung T.N., Lau T.K., Chang A.M., Hjelm N.M. Rapid clearance of fetal DNA from maternal plasma. Am. J. Hum. Genet. 1999, 64:218-224.
163. Yu S.C., Lee S.W., Jiang P., Leung T.Y., Chan K.C., Chiu R.W., et al. High-resolution profiling of fetal DNA clearance from maternal plasma by massively parallel sequencing. Clin. Chem. 2013, 59:1228-1237.
164. Galluzzi L., Kepp O., Krautwald S., Kroemer G., Linkermann A. Molecular mechanisms of regulated necrosis. Semin. Cell Dev. Biol. 2014, 35C:24-32.
165. Dorn G.W. Molecular mechanisms that differentiate apoptosis from programmed necrosis. Toxicol. Pathol. 2013, 41:227-234.
166. Wickman G., Julian L., Olson M.F. How apoptotic cells aid in the removal of their own cold dead bodies. Cell Death Differ. 2012, 19:735-742.
167. van der Vaart M., Pretorius P.J. The origin of circulating free DNA. Clin. Chem. 2007, 53:2215.
168. Schwarzenbach H., Hoon D.S., Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 2011, 11:426-437.
169. Mouliere F., Thierry A.R. The importance of examining the proportion of circulating DNA originating from tumor, microenvironment and normal cells in colorectal cancer patients. Expert Opin. Biol. Ther. 2012, 12(Suppl. 1):S209-S215.
170. Garcia-Olmo D.C., Samos J., Picazo M.G., Asensio A.I., Toboso I., Garcia-Olmo D. Release of cell-free DNA into the bloodstream leads to high levels of non-tumor plasma DNA during tumor progression in rats. Cancer Lett. 2008, 272:133-140.
171. Thierry A.R., Mouliere F., Gongora C., Ollier J., Robert B., Ychou M., et al. Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. Nucleic Acids Res. 2010, 38:6159-6175.
172. Newman A.M., Bratman S.V., To J., Wynne J.F., Eclov N.C.W., Modlin L.A., et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat. Med. 2014, 20:548-554.
173. Silva J.M., Silva J., Sanchez A., Garcia J.M., Dominguez G., Provencio M., et al. Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival. Clin. Cancer Res. 2002, 8:3761-3766.
174. Alix-Panabieres C., Schwarzenbach H., Pantel K. Circulating tumor cells and circulating tumor DNA. Annu. Rev. Med. 2012, 63:199-215.
175. Koyanagi K., Mori T., O'Day S.J., Martinez S.R., Wang H.J., Hoon D.S. Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. Cancer Res. 2006, 66:6111-6117.
176. Hoon D.S.B., Spugnardi M., Kuo C., Huang S.K., Morton D.L., Taback B. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene 2004, 23:4014-4022.
177. Surova O., Zhivotovsky B. Various modes of cell death induced by DNA damage. Oncogene 2013, 32:3789-3797.
178. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
179. Schwarzenbach H., Stoehlmacher J., Pantel K., Goekkurt E. Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer. Ann. N. Y. Acad. Sci. 2008, 1137:190-196.
180. Chan K.C., Leung S.F., Yeung S.W., Chan A.T., Lo Y.M. Persistent aberrations in circulating DNA integrity after radiotherapy are associated with poor prognosis in nasopharyngeal carcinoma patients. Clin. Cancer Res. 2008, 14:4141-4145.
181. Salani R., Davidson B., Fiegl M., Marth C., Muller-Holzner E., Gastl G., et al. Measurement of cyclin E genomic copy number and strand length in cell-free DNA distinguish malignant versus benign effusions. Clin. Cancer Res. 2007, 13:5805-5809.
182. Gilbert M.T., Haselkorn T., Bunce M., Sanchez J.J., Lucas S.B., Jewell L.D., et al. The isolation of nucleic acids from fixed, paraffin-embedded tissues-which methods are useful when?. PLoS One 2007, 2(6):e537.
183. Lo Y.M., Tein M.S., Lau T.K., Haines C.J., Leung T.N., Poon P.M., et al. Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. Am. J. Hum. Genet. 1998, 62:768-775.
184. Lun F.M., Chiu R.W., Chan K.C., Leung T.Y., Lau T.K., Lo Y.M. Microfluidics digital PCR reveals a higher than expected fraction of fetal DNA in maternal plasma. Clin. Chem. 2008, 54:1664-1672.
185. Yu H., Shen Y., Ge Q., He Y., Qiao D., Ren M., et al. Quantification of maternal serum cell-free fetal DNA in early-onset preeclampsia. Int. J. Mol. Sci. 2013, 14:7571-7582.
186. Smid M., Galbiati S., Lojacono A., Valsecchi L., Platto C., Cavoretto P., et al. Correlation of fetal DNA levels in maternal plasma with Doppler status in pathological pregnancies. Prenat. Diagn. 2006, 26:785-790.
187. Chan K.C., Zhang J., Hui A.B., Wong N., Lau T.K., Leung T.N., et al. Size distributions of maternal and fetal DNA in maternal plasma. Clin. Chem. 2004, 50:88-92.
188. Menkveld R. Clinical significance of the low normal sperm morphology value as proposed in the fifth edition of the WHO Laboratory Manual for the Examination and Processing of Human Semen. Asian J. Androl. 2010, 12:47-58.
189. Shamsi M.B., Imam S.N., Dada R. Sperm DNA integrity assays: diagnostic and prognostic challenges and implications in management of infertility. J. Assist. Reprod. Genet. 2011, 28:1073-1085.
190. Agarwal A., Said T.M. Role of sperm chromatin abnormalities and DNA damage in male infertility. Hum. Reprod. Update 2003, 9:331-345.
191. Ahmadi A., Ng S.C. Fertilizing ability of DNA-damaged spermatozoa. J. Exp. Zool. 1999, 284:696-704.
192. Bungum M. Sperm DNA integrity assessment: a new tool in diagnosis and treatment of fertility. Obstet. Gynecol. Int. 2012, 2012(531042):1-6.